Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655130 add-on proof-of-concept study in ulcerative colitis during TNF inhibitor therapy
NL-OMON47670Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing BI 655130 add-on with Placebo add-on (2 arms). Primary endpoint: Mucosal healing at Week 8. Started Aug 2017; status: active, not recruiting.
02
Drugs
spesolimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON47670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47670.